Ophthalmic ointments comprising valganciclovir hydrochloride for treating infective eye diseases
AssigneeSkiron Biosciences
InventorANTON DELWIG
Life of this patent
Estimating the term…
Abstract
The present invention provides ophthalmic ointments for treating infective eye diseases containing valganciclovir hydrochloride as an active ingredient in the amount of from about 0.01% to about 10.0% w/w. These ophthalmic ointments are particularly effective for treating eye diseases caused by herpesviruses in the eye. Compared with oral administration, topical administration of valganciclovir hydrochloride is not accompanied by systemic side effects such as bone marrow suppression. Compared with topical administration of ganciclovir, topical administration of valganciclovir hydrochloride is much more effective in treating infective diseases in the eye and is not accompanied by toxicity to the surface of the eye.
Claims20
An ophthalmic ointment for treating an infective eye disease comprising as an active ingredient from about 0.01% to about 10.0% w/w of valganciclovir hydrochloride.
Dependencies are inferred from the claim text.